Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BIOCRYST PHARMACEUTICALS INC : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

09/14/2022 | 04:13pm EST

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 9, 2022, BioCryst Pharmaceuticals, Inc. (the "Company") approved certain changes to its Leadership Team. Effective September 15, 2022, William P. Sheridan, MBBS, will serve as Chief Development Officer of the Company. Dr. Sheridan has served as the Company's Chief Medical Officer since joining the Company in July 2008, and in his new role, he will focus on advancing the Company's significant pipeline of development candidates.

Also effective September 15, 2022, Dr. Ryan Arnold will serve as the Company's new Chief Medical Officer. He has served as Senior Vice President, Global Medical Affairs of the Company since March 2022 and has more than 20 years of industry experience, including prior roles with increasing levels of responsibility in the medical affairs function at multiple companies.

Dr. Arnold joins Dr. Sheridan and Dr. Helen Thackray, the Company's Chief Research and Development Officer, as physicians on the Company's Leadership Team.

Item 7.01. Regulation FD Disclosure.

On September 14, 2022, the Company issued a press release announcing the events described in Item 5.02 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.    Description

                 Press release dated September 14, 2022 entitled "BioCryst Names
  99.1         Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan
               Arnold Chief Medical Officer"
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document)

© Edgar Online, source Glimpses

All news about BIOCRYST PHARMACEUTICALS, INC.
11/11BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction..
AQ
11/10BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction..
AQ
11/10Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction..
CI
11/09BioCryst to Present at Upcoming Investor Conferences
AQ
11/07BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635
AQ
11/04BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
AQ
11/04BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/02Evercore ISI Upgrades BioCryst Pharmaceuticals to Outperform From In Line With $16 Pric..
MT
11/02RBC Trims BioCryst Pharmaceuticals' Price Target to $13 From $14 on Revised Estimates, ..
MT
11/01BioCryst Pharmaceuticals Q3 Loss Narrows as Revenue Grows
MT
More news
Analyst Recommendations on BIOCRYST PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 267 M - -
Net income 2022 -212 M - -
Net cash 2022 54,9 M - -
P/E ratio 2022 -10,9x
Yield 2022 -
Capitalization 2 289 M 2 289 M -
EV / Sales 2022 8,36x
EV / Sales 2023 6,68x
Nbr of Employees 358
Free-Float 99,0%
Chart BIOCRYST PHARMACEUTICALS, INC.
Duration : Period :
BioCryst Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCRYST PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 12,28 $
Average target price 17,60 $
Spread / Average Target 43,3%
EPS Revisions
Managers and Directors
Jon P. Stonehouse Chief Executive Officer & Director
Michael L. Jones Executive Director-Finance
Anthony Doyle Chief Financial Officer
Robert Alexander Ingram Chairman
Helen M. Thackray Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOCRYST PHARMACEUTICALS, INC.-11.34%2 289
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930